The Year in Cardiology 2018: Valvular Heart Disease
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
In 2018, the publications on valvular heart disease (VHD) addressed all topics—epidemiology, diagnosis, therapy, and predictors of outcome—but were dominated by studies focusing on transcatheter treatment. Regarding mitral regurgitation (MR) two pivotal studies investigating transcatheter edge-to-edge repair for secondary MR as well as early clinical experience with transcatheter mitral valve replacement (TMVR) were published. Regarding aortic stenosis (AS) there is a clear trend towards the expansion of indications for transcatheter aortic valve implantation (TAVI) to intermediate and low-risk groups, bicuspid aortic valve (BAV) and failed surgically implanted bioprostheses. Tricuspid valve (TV) disease is a growing clinical problem associated with high morbidity and mortality. Isolated TV surgery has a high risk and is currently performed in a minority of patients. Novel therapies using the edge-to-edge approach or annuloplasty are being investigated. Transcatheter aortic valve implantation is rapidly evolving, and implantation numbers are steeply increasing. In Germany where all procedures are mandatorily registered in a quality control programme, more than 15 000 TAVI procedures were performed in 2016. The number more than tripled since 2011, while isolated surgical aortic valve replacement (SAVR) remained relatively stable with approximately 10 000 per year being performed now much less frequently than TAVI (Figure 1). Complication rates and mortality decreased continuously with overall in-hospital mortality being in 2016 for the first time similar for TAVI (2.6%) and SAVR (2.9%) despite the different risk profile of both patient groups.1 Expanding adoption of TAVI across the risk strata is widespread both in Europe and the USA. Based on SURTAVI, Sapien3 Intermediate Risk and PARTNER 2A the safety and efficacy was established for intermediate risk and following the NOTION study the concept showed promising results for low-risk patients.2 Importantly, surgical risk scales used for both approaches tend to overestimate mortality for TAVI patients in all the risk strata even taking into consideration that low-risk patients undergoing TAVI are younger than SAVR (Figure 2). The recent FDA-approved low-risk TAVR trial prospectively studied the outcomes of transfemoral TAVI in the low-risk group (STS-PROM ≤3%) and compared the results to historical controls from the Society of Thoracic Surgeons (STS) database. No mortality and strokes at 30 days, low risk of paravalvular regurgitation as well as permanent pacemaker implantation (PPI) rates similar to SAVR were reported, however, frailty was an exclusion criterium.3 A sub-analysis of the randomized controlled SURTAVI trial evaluating patients with STS-PROM <3% suggested that TAVI may achieve superior early clinical outcomes compared with SAVR.4 These findings support the need for an adequately powered randomized trial to compare TAVI with SAVR in patients at low operative risk. Apparently, in such a population with assumingly longer life expectancy, there is a clear need for data on the long-term durability because no follow-up beyond 2 years has so far been published for this population. Ongoing trials such as PARTNER3, Evolut R Low Risk and NOTION 2 with follow-up of 5–10 years will provide more data with this regard. Currently available long-term durability data for transcatheter aortic valves although promising are unfortunately limited by the poor survival of the high-risk early populations. Eltchaninoff et al.5 reported an incidence of structural valve deterioration of 3.2% and bioprosthetic valve failure of 0.58% at 8 years using the new European consensus definition. Holy et al.6 estimated from their series that the rate of bioprosthetic valve failure at 8 years was 7.9% for the actuarial and 4.5% for the actual analysis. However, long-term durability will remain one of the key concerns until we have more solid data. Numbers of procedures (A) and in-hospital mortality (B) related to transvascular transcatheter aortic valve implantation, transapical TAVI, and isolated surgical aortic valve replacement. Data from the German Institute for Quality Assurance and Transparency in Healthcare (IQTIG) report. Reprinted with permission from Gaede et al.,1 combining Figures 1 and 3. Different performance of surgical risk scores in surgical aortic valve replacement and transcatheter aortic valve implantation patients across the risk strata. Reprinted from Tarantini et al.2 One of the other concerns beyond durability is the need for PPI which is in most reports higher with TAVI than with SAVR. A recent systematic review demonstrated the highly variable risk of PPI (2.3–36.1%) due to new onset conduction abnormalities after TAVI.7 The risk tended to be lower after balloon-expandable than self-expandable valves. Procedural factors, such as the depth of implantation, predilatation, distribution of calcifications, and pre-existing conduction abnormalities were important
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcatheter Mitral-Valve Repair in Patients with Heart Failure
Stone, G. W., Lindenfeld, J., Abraham, W. T., Kar, S., Lim, D. S., Mishell, J. M., Whisenant, B., Grayburn, P. A., Rinaldi, M., Kapadia, S. R., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1806640 · Cited by 3,017
Cited by
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., Delling, F. N., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000950 · Cited by 5,784
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Metadata
- Authors
- Wojakowski, W., & Baumgartner, H.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01-02
- Volume
- 40
- Issue
- 5
- Pages
- 414-421
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2908106077
- Cited by
- 9
- References
- 1
- FWCI
- 0.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Year in Cardiology 2018: Valvular Heart Disease. https://app.cochat.ai/papers/10.1093/eurheartj/ehy893
- The paper
- Wojakowski, W., & Baumgartner, H. (2019). The Year in Cardiology 2018: Valvular Heart Disease. European Heart Journal. https://doi.org/10.1093/eurheartj/ehy893
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.